1. Home
  2. CRESY vs ARVN Comparison

CRESY vs ARVN Comparison

Compare CRESY & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cresud S.A.C.I.F. y A.

CRESY

Cresud S.A.C.I.F. y A.

HOLD

Current Price

$11.69

Market Cap

718.2M

Sector

Finance

ML Signal

HOLD

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$7.64

Market Cap

658.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRESY
ARVN
Founded
1936
2015
Country
Argentina
United States
Employees
2889
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
718.2M
658.2M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
CRESY
ARVN
Price
$11.69
$7.64
Analyst Decision
Buy
Analyst Count
0
19
Target Price
N/A
$15.05
AVG Volume (30 Days)
273.7K
694.3K
Earning Date
05-07-2026
05-04-2026
Dividend Yield
8.14%
N/A
EPS Growth
N/A
58.84
EPS
N/A
N/A
Revenue
N/A
$262,600,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$6.92
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.39
$6.06
52 Week High
$14.21
$14.22

Technical Indicators

Market Signals
Indicator
CRESY
ARVN
Relative Strength Index (RSI) 50.65 37.96
Support Level $10.90 $7.35
Resistance Level $12.26 $10.18
Average True Range (ATR) 0.58 0.42
MACD 0.06 0.05
Stochastic Oscillator 42.31 31.43

Price Performance

Historical Comparison
CRESY
ARVN

About CRESY Cresud S.A.C.I.F. y A.

Cresud SACIF y A is a Latin American agricultural firm producing basic commodities with a growing presence in Argentina, Brazil, and other countries through its investment in Brasilagro. It focuses on grains, sugarcane, and cattle farming, acquiring and developing agricultural properties for production or value appreciation, and occasionally selling appreciated land. It also leases land and offers agency and agro-industrial services. Operations are divided into two segments: agricultural business (production, land transformation and sales, corporate services) and urban properties and investments (shopping malls, offices, sales, developments, hotels, and related activities).

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Share on Social Networks: